Ovarian cancer is highly metastatic with a poor prognosis. The serine/threonine kinase, p70 S6 kinase (p70 S6K ), which is a downstream effector of phosphatidylinositol 3-kinase/Akt pathway, is frequently activated in ovarian cancer. Here, we show that p70 S6K is a critical regulator of the actin cytoskeleton in the acquisition of the metastatic phenotype. This regulation is through two important activities: p70 S6K acts as an actin filament cross-linking protein and as a Rho family GTPase-activating protein.
Introduction
Ovarian cancer is the leading cause of death among all gynecological malignancies (Jemal et al., 2009) . Nearly 70% of patients are diagnosed at the advanced stages, which have already metastasized cancer cells that detach from the primary tumor, spread throughout the peritoneum forming malignant ascites, adhere to and eventually invade organs within the peritoneal cavity. No effective therapy for advanced or metastatic ovarian carcinoma is currently available, and the 5-year survival rate is o25%. Thus, it is important to better understand the mechanisms by which these cells acquire metastatic properties and to identify new potential molecular targets.
The p70 S6 kinase ( p70 S6K ) is a downstream effector of the phosphatidylinositol 3-kinase/Akt pathway, which is frequently activated in human ovarian cancer (Shayesteh et al., 1999; Philp et al., 2001; Altomare et al., 2004) . The p70 S6K is also well known to be activated by cytokines and growth factors, including epidermal growth factor and hepatocyte growth factor (HGF), which are potent inducers of p70 S6K in ovarian cancer (Liu et al., 2006; Zhou and Wong, 2006) . Constitutive activation of p70 S6K is significantly more prevalent in malignant ovarian tumors than in benign lesions (Castellvi et al., 2006) . Recently, in addition to its well-established role in regulating proliferation and cell survival, we show for the first time that p70 S6K may be involved in other aspects of ovarian cancer progression, such as metastasis (Wong et al., 2004; Zhou and Wong, 2006; Pon et al., 2008) . However, the role of p70 S6K in cell migration, which is a key process directly linked to cancer invasion and metastasis, has not been established, and the mechanism by which p70 S6K contributes to this process is also unknown.
Reorganization of the actin cytoskeleton is both essential and central for cell migration (Pantaloni et al., 2001) . Motile cancer cells must assemble and disassemble the actin filaments at their leading edges as they move forward. Thus, deregulation of the expression or properties of actin-binding proteins that regulate the polymerization/depolymerization of actin into filaments, and cross-linking of these into bundles could influence metastasis (Pawlak and Helfman, 2001 ). The Rho family of small GTPases, in particular Rac1, Cdc42 and RhoA, are molecular switches that control the organization and dynamics of the actin cytoskeleton (Ridley et al., 2003; Raftopoulou and Hall, 2004) : Rac1 regulates the formation of membrane ruffles (lamellipodia), Cdc42 triggers membrane projections (filopodia) and RhoA regulates stress fiber and focal adhesions. In addition, Rac1 is essential for forward cellular movement and Cdc42 is required for dictating the direction of migration.
In the present study, we show for the first time a role for p70 S6K in the directed migration of human ovarian cancer cells. We also provide mechanistic insights suggesting that this tumorigenic activity is associated with the ability of p70 S6K to directly and indirectly reorganize the actin cytoskeleton through its actin filament cross-linking and Rac1/Cdc42-activating activities.
Results

p70
S6K activation causes reorganization of the actin cytoskeleton The rapid reorganization of the actin cytoskeleton is a critical early event in cell migration (Pantaloni et al., 2001) . To address if p70 S6K modifies actin organization in the cell, we tested the effects of constitutively active p70 S6K activation on the actin cytoskeleton in CaOV-3 and SKOV-3 ovarian cancer cell lines, which represent advanced human ovarian cancer (Buick et al., 1985) . When constitutively active p70 S6K (DN 54 DC 104 and D 3 E-E 398 ) was ectopically expressed, there was a marked difference in both cellular morphology and actin cytoskeleton architecture. DN 54 DC 104 -and D 3 E-E 398 -transfected cells had prominent actin-rich projections in the form of lamellipodia, actin microspikes and filopodia, which were absent in the untransfected cells ( Figure 1a ). Even after 24 h, there were no protrusions present in the control cells (data not shown).
To further demonstrate the effect of p70 S6K in altering the actin cytoskeleton, we utilized a small interfering RNA (siRNA) specifically engineered towards p70 S6K . In these studies, HGF was used to activate endogenous p70 S6K , because HGF is highly expressed in ovarian cancer ascites inducing migration of cultured ovarian cancer cells (Sowter et al., 1999) . Overexpression of the HGF receptor Met is associated with ovarian cancer progression and high Met expression correlates with poor survival (Sawada et al., 2007) . The p70 S6K -specific siRNA, but not the nonspecific siRNA, was effective in depleting p70 S6K expression as confirmed by western blotting (Figure 1b, inset) . We observed that p70 S6K siRNA-treated ovarian cancer cells resulted in dramatically reduced HGF-stimulated actin reorganization and reduced formation of membrane protrusions (Figure 1b) . A second p70 S6K -specific siRNA was also used, and comparable results were obtained, which confirms that p70 S6K was responsible for this effect (data not shown). In contrast, nonspecific siRNA did not obviously alter the pattern of actin distribution. Similar results were observed in cells treated with rapamycin, which is a small molecule inhibitor of p70 S6K kinase activity (Figure 1b) . Together, these data show that p70 S6K activation has a critical role in the reorganization of actin cytoskeleton.
S6K is required for directional migration As directed cell migration is a prerequisite of metastasis, we assessed the role of p70 S6K on cell migration using scrape wounding assays combined with Golgi tracking (Ridley et al., 2003) . We found that p70 S6K siRNAtreated cells migrated less efficiently than the control nonspecific siRNA-treated cells, and also exhibited significantly reduced directional persistence (98% inhibition of a polarized orientation of the Golgi apparatus) in the presence of HGF (Figure 2a ). The role of p70 S6K in directional cell migration was further evaluated by measuring the movement of the cells towards a chemotactic stimulus using Boyden chamber assays. Activation of p70 S6K significantly promoted a motile phenotype, as detected by a 2.8-fold increase in cell motility compared with control cells (Figure 2b ). In contrast, the HGF-enhanced migration was effectively suppressed by siRNA-mediated depletion of p70 S6K to near basal levels ( Figure 2b ). Under these conditions, and consistent with previous observation (Corps et al., 1997) , HGF did not cause significant alterations of cell proliferation (Supplementary Figure 1) . We also found no effect of constitutively active p70 S6K on cell proliferation ( Supplementary Figure 1) , indicating that the increase in cell migration was not because of a proliferative effect.
S6K binds directly to actin To begin to understand the mechanism of p70 S6K involvement in signaling the actin cytoskeleton, we used a cosedimentation assay to investigate if p70 S6K binds actin filament in vitro. As shown in Figure 3a , endogenous active p70 S6K readily cosedimented with actin. Moreover, stimulation of HGF increased the amount of phospho-p70 S6K sedimented in the actin pellet, suggesting that activated p70 S6K can more capably associate with actin.
We further asked whether the interaction of p70 S6K with actin by direct interaction or is mediated by other actin-binding proteins. To test this, an in vitro actin binding assay was performed using highly purified active p70
S6K
. Figure 3b shows that the purified p70 S6K could be readily coprecipitated with actin in a concentrationdependent manner. The p70 S6K alone did not pellet, indicating that the pelleting is because of binding to F-actin (Figure 3c ). The fact that no other proteins were involved indicates a direct association between p70 S6K and actin.
This interaction was additionally verified by colocalization analysis using immunofluorescence microscopy. Although phospho-p70 S6K was located diffusely through the control cells, it was translocated to and, interestingly, concentrated in lamellipodia, actin microspikes and filopodia where it was extensively colocalized with actin upon stimulation with HGF (Figure 3d, left) . We CaOV-3 SKOV-3
CaOV-3 SKOV-3 β-actin 
p70
S6K cross-links and stabilizes F-actin To further establish the role that p70 S6K has in the actin cytoskeleton, we repeated the cosedimentation assay, this time using a low-speed (14 000 g) to pellet the bundled or cross-linked actin filaments, while the free actin filaments remain in the supernatant. HGF caused the majority of actin filaments to pellet with endogenous phospho-p70 S6K during low-speed centrifugation, suggesting that active p70 S6K is cross-linking individual filaments into actin bundles ( Figure 4a and Supplementary Figure 2c ). This was also examined using purified proteins: F-actin was detected in the supernatant when p70 S6K was absent, but in the pellet when p70 S6K was present, with an increasing shift between free to bundled actin with increasing molar concentrations of p70 , suggesting that more actin bundles were formed (Figure 4c ). We also used electron microscopy to visualize the F-actin bundling. In the absence of p70 S6K , actin filaments formed a uniform meshwork of fine filaments, but did not show bundling. In contrast, robust multifilament bundles were clearly seen (Figure 4d ). These closely apposed bundles were often slightly curved, suggesting flexible cross-linking.
The possibility of a physical interaction between p70 S6K and actin suggests that p70 S6K may affect the kinetics of actin polymerization. The p70 S6K did not change the rate or the extent of polymerization, suggesting that unlike other common activities of these proteins, actin polymerization is not a generic property of p70 S6K (Figure 5a ). On the other hand, p70 S6K significantly decreased the rate and extent of actin filament depolymerization (Figure 5b ). Fluorescence from pyrene-labeled F-actin decreased rapidly after addition of cofilin. This decrease in fluorescence was largely reduced with F-actin preincubated with purified p70 S6K , suggesting p70 S6K prevented depolymerization of F-actin induced by cofilin. These results indicate that in addition to cross-linking of F-actin, p70
S6K also stabilizes filaments.
p70 S6K induces activation of Rac1 and Cdc42
We next sought to determine the molecular mechanism by which p70 S6K regulates actin organization. Three members of the Rho family GTPases, Rac1, Cdc42 and RhoA, are best known for their effects on the actin cytoskeleton (Hall, 1998) . In fibroblasts, it has been shown that Rho GTPases have the potential to regulate p70 S6K , suggesting that p70 S6K may be a downstream effector (Chou and Blenis, 1996; Berven et al., 2004) . However, transfection with dominant negative Rac (N17Rac1), Cdc42 (N17Cdc42), or Rho (N19RhoA) failed to block p70 S6K phosphorylation (activation) upon HGF stimulation in CaOV-3 cells (Supplementary Figure 3a) . Similarly, ectopic expression of constitutively active Rac (L61Rac1), Cdc42 (V12Cdc42) and Rho (V14RhoA) were unable to activate p70 S6K (Supplementary Figure 3b) .
As its roles in actin cytoskeleton reorganization similar to the activation of Rho GTPases, we investigated if p70 S6K might act upstream of Rho GTPases. To explore this possibility, we tested the effects of p70 S6K on Rac1, Cdc42 and RhoA activation using a pull-down assay that specifically recognizes the active GTP-bound form. As shown in Figure 6a , HGF rapidly increased . In addition, expression of active p70 S6K potently stimulated the activation of both Rac1 and Cdc42, whereas it did not have an effect on RhoA (Figure 6a ), which is consistent with its enrichment in lamellipodia and filopodia (Figure 1 ). To further elucidate the activation of Rac1 and Cdc42 was p70 S6K specific, we used siRNA. In cells transfected with p70 S6K siRNA, but not control siRNA, the ability of HGF to activate Rac1 and Cdc42 was abrogated (90% inhibition) (Figure 6b) . Similarly, HGF-dependent activation of Rac1 and Cdc42 was also blocked in the presence of rapamycin (80% inhibition) (Figure 6c ). Similar results were obtained with SKOV-3 cells ( Supplementary  Figures 2d and e) . These results identify p70 S6K as an upstream regulator of Rac1 and Cdc42. shown to clearly inhibit the p70 S6K -induced restructuring of the actin cytoskeleton (Figure 7a ). Conversely, constitutively active Rac1 and Cdc42 enhanced cell spreading and caused reorganization of the actin cytoskeleton (lamellipodia/filopodia) to levels similar to those observed in p70 S6K -expressing cells (Figure 7b ). To explore the relationship between p70 S6K and Rac1/ Cdc42, we investigated a possible interaction between these two proteins. Figure 7c demonstrates a colocalization of phospho-p70 S6K with Rac1/Cdc42 in HGFstimulated cells, but not in control cells.
The p21-activated kinase (PAK1) is a well-characterized effector of both Rac1 and Cdc42 and is essential for regulating leading edge actin dynamics (Dummler et al., 2009) . Our finding that the activities of both Rac1 and Cdc42 are important in p70 S6K -mediated actin cytoskeleton reorganization prompted us to assess the role of PAK. We found that p70 S6K was able to stimulate the phosphorylation of PAK1, and that stimulation was lost in HGF-treated cells transfected with the p70 S6K siRNA (Figure 8a ). Knocking down PAK1 impaired the pronounced lamellipodia/filopodia phenotype in response to transfection of constitutively active p70 S6K (Figure 8b ). These cells also displayed a loss of the motile phenotype (Figure 8c ). Another PAK1 siRNA also showed comparable results (Figure 8) , whereas a nonspecific siRNA had no effect. These data demonstrate an essential role of Rac1/Cdc42/PAK1 signaling in actin cytoskeleton reorganization and the regulation of ovarian cancer cell motility downstream of p70 S6K .
Discussion
In this study, we have successfully identified p70 S6K as a novel regulator of the actin cytoskeleton and found that it is pivotal for the directed migration of ovarian cancer cells. We show that two important properties underlie this function of p70 S6K , namely actin cross-linking and Rac1 and Cdc42 activation (Figure 9 ). Several aspects of this function are worth highlighting. We showed for the first time that p70 S6K was able to bind to F-actin with no other proteins involved, indicating direct binding of p70 S6K to F-actin. The finding that p70 S6K -F-actin structures were cytochalasin D sensitive emphasizes the possibility that in vitro interactions of p70 S6K with F-actin may represent direct interactions of p70 S6K with actin filaments in vivo. Moreover, the binding of p70 S6K to F-actin was more potent in the presence of phosphorylation than in its absence, suggesting a dynamic regulation of p70 S6K association with the cytoskeleton and reinforces the notion that actin reorganization and cell migration are finely tuned events. This also implies that the actin-binding domain in p70 S6K may normally be hidden when this protein is in an inactive conformation.
An intriguing aspect concerns the biological function of such an interaction. The finding that p70 S6K both cross-links and stabilizes actin filaments suggests a role 
p70
S6K signaling to the actin cytoskeleton CKM Ip et al for p70 S6K in regulating actin dynamics. Several key actin-binding proteins, such as a-actinin, fimbrin and fascin also function to regulate actin bundling (Holmes et al., 1976; Hanein et al., 1997) . As p70 S6K has a wellestablished role in protein synthesis, this interaction may also have significance in synthesizing local proteins important for propagating the migratory response. For example, b-actin mRNA has been shown to localize to the leading lamella and its active translation there is important for cell migration Latham et al., 1994) .
The Rho family of GTPases are critical regulators of actin reorganization. Studies using fibroblasts have suggested that Rho GTPases and p70 S6K may reside on a common signaling pathway, and indeed these studies indicate that Rho GTPases are upstream activators of p70 S6K (Chou and Blenis, 1996; Berven et al., 2004) . In contrast to the above data, we found that, in ovarian cancer cells, Rac1 and Cdc42 did not regulate p70 . One possible explanation is that this action may be cell-type dependent. Clearly, epithelial cells and fibroblasts display distinct architecture of the actin cytoskeleton. Rac has been demonstrated to evoke different responses depending on the cell type (Takaishi et al., 1997; Sander et al., 1998) . Another possibility, and one that is supported by the findings reported here, is that it may be related to the different functions of p70
S6K
. It is interesting to note that activation of p70 S6K by Rac1 and Cdc42 appears to be independent of the ability of these Rho GTPases to regulate the cytoskeleton (Chou and Blenis, 1996) . In contrast, we show that Rac and Cdc42 mediate signaling from p70 S6K is related to cytoskeletal reorganization, which Rac/Cdc42 are known to function during this process (Hall, 1998) .
The increase in Rac1 and Cdc42 activities in response to p70 S6K sheds new light on the biochemical mechanism of p70 S6K function and identifies p70 S6K as a novel, important regulator of Rho GTPases. How does p70 S6K control the function of Rac1/Cdc42? Guanine nucleotide exchange factors (GEFs) are known to activate Rho GTPases by regulating the exchange of GDP for GTP. The Dbl homology-Pleckstrin homology motif, present in many of proteins such as GEFs, is responsible for activation of Rac1 and Cdc42 (Erickson and Cerione, 2004) . However, p70 S6K does not contain a Dbl homology-Pleckstrin homology domain or other motifs that may elicit GEF activity. Given the fact that TOR S6K siRNA or (c) treated with rapamycin (Rp) before HGF stimulation. Lysates were analyzed for GTPase activation using pull-down assays as described in Materials and methods. GTP-bound (active) Rac1, Cdc42 and RhoA were examined by western blotting. Alternatively, lysates were resolved in SDS-PAGE and blotted with anti-phospho (p)-p70 S6K , total p70 S6K and Rac1, Cdc42 and RhoA. GTPgS served as a positive control and GDP was a negative control. The blots represent three independent experiments performed with similar results.
p70
S6K signaling to the actin cytoskeleton CKM Ip et al proteins regulate Rho GTPase activity through a GTP exchange factor, ROM2, in yeast (Schmidt et al., 1997) , it is possible that an additional protein, such as GEF, may be necessary for p70 S6K -mediated Rac1/Cdc42 activation. We also showed an essential role for PAK1 in Rac1/Cdc42-mediated actin cytoskeleton reorganization downstream of p70
S6K
. This finding is intriguing because PAK1 has been observed as the predominant isoform that is frequently activated in ovarian tumors and appears to be associated with tumor aggressiveness (Schraml et al., 2003; Siu et al., 2009) . Once activated, PAK1 may locally affect the actin organization through S6K signaling to the actin cytoskeleton CKM Ip et al direct phosphorylation of key signaling targets. For example, PAK1 phosphorylates and inactivates the actin-depolymerizing protein cofilin leading to actin filament stabilization (Dummler et al., 2009) . The observation that p70 S6K can also physically cross-link and stabilize the filaments suggests that multiple mechanisms that control stable actin structures are likely to be regulated by p70 S6K and gives support that this kinase is a critical regulator of the actin cytoskeleton. The ability of p70 S6K to modulate dynamics of the actin cytoskeleton suggests that many oncogenic pathways could govern tumor invasion/metastasis by modulating p70
. The p70 S6K activation did not cause significant alteration to the actin cytoskeleton of normal ovarian surface epithelium (OSE) (Supplementary  Figure 4) , which suggests that the effect may be specific to ovarian cancer cells. It also complements our previous finding and other studies that showed a differential effect on OSE (Wong et al., 2004; Theriault et al., 2007) and the acquisition of a motile, fibroblastlike phenotype in OSE may be regulated independent of phosphatidylinositol 3-kinase and is a slow process (Ahmed et al., 2006) . We and others have described the frequent activation of p70 S6K in ovarian cancer cells than in normal OSE, suggesting a critical role for p70 S6K in ovarian cancer development and progression (Wong et al., 2004; Castellvi et al., 2006; Pon et al., 2008) . The observation that p70 S6K was highly expressed and activated in high-grade, poorly differentiated ovarian carcinomas further suggests that p70 S6K may be associated with tumor aggressiveness. Possible involvement of p70 S6K in the regulation of cell migration is also particularly intriguing because the malignant phenotypes from patients with advanced breast cancer, colon cancer and hepatocellular carcinoma are also correlated with increased activation of p70 S6K (Filonenko et al., 2004; Sahin et al., 2004; Nozawa et al., 2007) . We found that active p70 S6K was able to bind and cross-link actin filaments and regulate actin organization in HepG2 liver cancer cells (Supplementary Figure 5) , further suggesting that the cytoskeletal function of p70 S6K we propose here may have broad implications for other tumor cell types as well.
In summary, the present study reveals the novel identification of the localization and function of p70 S6K in the actin cytoskeleton. The results show that p70 S6K has pivotal roles in regulating metastatic progression, and opens new areas for further investigation. Such findings greatly advance our understanding of the role of p70 S6K in oncogenesis and highlight the usefulness of targeting p70 S6K to impede metastasis in ovarian cancer.
Materials and methods
Cells and cell culture
Institutional approval for experimentation with human tissues was obtained before this study. OSE-529, OSE-545 and OSE-547 were obtained from ovaries at laparoscopy from women having surgery for non-malignant gynecologic diseases. The human ovarian carcinoma cell lines CaOV-3 and SKOV-3 were gifts from Dr N Auersperg (University of British Columbia, Vancouver, BC, Canada). Cells were cultured in media 199:MCDB105 supplemented with 10% fetal bovine serum for OSE and 5% fetal bovine serum for ovarian cancer cell lines. HepG2 human liver cancer cell line was maintained in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum. Cells were grown in humidified atmosphere of 5% CO 2 at 37 1C.
DNA constructs and transfection
N17Rac1 and L61Rac1 constructs were kindly provided by Dr A Hall (Memorial Sloan-Kettering Cancer Center, New York, NY) (Olson et al., 1995) . N17Cdc42, V12Cdc42, N19RhoA and V14RhoA were obtained from UMR cDNA Resource Center (Rolla, MO, USA). The myc-tagged constitutively active p70 S6K (DN 54 DC 104 and D 3 E-E 398 ) were gifts from Dr G Thomas (Genome Research Institute, University of Cincinnati, Cincinnati, OH, USA) (Jefferies et al., 1997) . Green fluorescent protein-tagged D 3 E-E 398 was constructed by subcloning into pEGFP vector (Clontech, Palo Alto, CA, USA). To express complementary DNA constructs, cells were transiently transfected with 1 mg of plasmid DNA per well in 6-well plates using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
0 -CAUCAAA UAUCACUAAGUC-3 0 ; #2, 5 0 -CAACAAAGAACAAUC ACUA-3 0 ) and a nonspecific duplex oligo (5 0 -GGCTAC GTCCAGGAGCGCA-3 0 ) as a negative control were purchased from Dharmacon (Lafayette, CO, USA). Cells were transfected overnight with 20 nM of siRNA using siLectFect (Bio-Rad, Hercules, CA, USA) following the manufacturer's instruction.
Western blotting
Equal amounts of cell lysates were resolved by SDS-PAGE. The samples were incubated overnight at 4 o C with the following primary antibodies: anti-c-myc (clone 9E10) (1:1,500), anti-phospho-p70 S6K (Thr389) (1:1,000), anti-p70
S6K
(1:1,000), anti-phospho-S6 (Ser235/236) (1:1,000), anti-S6 (1:1,000), anti-phospho-PAK1 (Ser144)/PAK2 (Ser141) (1:1,000), anti-PAK1 in actin cytoskeleton reorganization and migration. The p70 S6K directly and indirectly reorganizes the actin cytoskeleton through crosslinking and stabilizing filaments and Rac1-and Cdc42-activating activities, which eventually leading to polarized actin structure and directed cell migration. 
Fluorescence microscopy
To detect F-actin, cells were fixed in 4% paraformaldehyde in phosphate-buffered saline. Cells were permeabilized with 0.1% Triton X-100, blocked with 5% bovine serum albumin and then incubated with Texas red-conjugated phalloidin (4 U/ml; Molecular Probes, Eugene, OR, USA) for 1 h at room temperature. Images were observed by confocal microscopy using a Leica DMRB (Leica, Solms, Germany). In some cases, cells were treated with 1 mM cytochalasin D (Calbiochem, San Diego, CA, USA) (known to disrupt actin filaments) for 30 min before fixation.
Actin binding assay
Binding of p70 S6K to actin was tested in a cosedimentation assay according to the manufacturer's instructions (Cytoskeleton, Denver, CO, USA). Briefly, cell lysates were first precleared by centrifugation at 800 g for 6 min and then incubated in the presence or absence of polymerized rabbit askeletal muscle actin at room temperature for 30 min. The reaction mixtures were centrifuged at 150 000 g for 90 min. Bovine serum albumin, which does not bind actin, and aactinin, an actin-binding protein, were used as negative and positive controls, respectively. The supernatant and pellet were separated and equal amounts were analyzed by western blotting using anti-phospho-p70 S6K antibody. To examine whether p70 S6K directly interacts with actin, purified recombinant human active p70 S6K (R&D Systems, Minneapolis, MN, USA) was used. After 1 h incubation at room temperature, actin filaments and bound purified proteins were pelleted by centrifugation at 100 000 g for 1 h at 20 1C. Equal amounts of the pellet and supernatant were analyzed by SDS-PAGE and Coomassie Blue staining.
Actin cross-linking assay Precleared cell lysates or purified p70 S6K (R&D Systems) was added to 4.5 mM freshly prepared F-actin for 1 h at room temperature, and was then centrifuged at 14 000 g for 1 min to sediment bundled F-actin, the linear, unbundled F-actin remains in the supernatant. Equal amounts of the pellet and supernatant were analyzed by SDS-PAGE and the gel was stained with Coomassie Blue.
Light scattering and electron microscopy Changes in light scattering of unlabeled actin was monitored by 901 light scattering at 405 nm (Perkin Elmer, Waltham, MA, USA). The change of light scattering was recorded after addition of polymerization buffer to purified p70 S6K and Gactin. Electron microscopy was performed on samples after actin polymerization was complete, as monitored by light scattering. Samples were fixed by 0.05% glutaraldehyde, spotted onto carbon-coated formvar grids and negative stained with 2% uranyl acetate. Images were recorded on a CCD camera with a Philips EM208s transmission electron microscope (Eindhoven, The Netherlands).
Actin polymerization assay Purified G-actin (2.5 mM, 10% pyrene-labeled) was incubated with purified p70 S6K for 30 min, and polymerization was initiated with 0.1 volume of 10 Â polymerization buffer. To measure cofilin-induced depolymerization, 1 mM polymerized filaments were incubated with purified p70 S6K for 30 min, and actin depolymerization was induced by the addition of 1 mM recombinant purified human cofilin (Cytoskeleton). The change in fluorescence was monitored over time with excitation at 355 nm and emission at 405 nm using a Victor X4 plate reader (Perkin Elmer).
Cell polarity and migration analysis Cells were cultured to confluency and scraped using a pipette tip. Cells at the wound edge with Golgi (anti-GM130, Sigma) polarized to the front-facing 120 1 sector were scored as positive for polarization. Migration assay was performed using a 24-well Transwell inserts (8 mm pore size; Millipore, Bedford, MA, USA). Cells (1.5 Â 10 4 per well) were placed in the upper chamber, and 5% serum was placed in the lower chamber as a chemoattractant. The migratory phenotype was determined by counting the cells that had migrated to the lower side of the filter. Results were presented as the mean cell number of five fields±s.d. of triplicate experiments.
Rac1, Cdc42 and RhoA activity assay Pull-down assays were performed to isolate the active GTPbound form using the Rac1/Cdc42 and RhoA activation assay kits (Upstate) following the manufacturer's instructions. Briefly, 10 mg of agarose conjugated GST-PAK-1 PBD fusion protein were added to the lysate and rotated for 1 h at 4 1C. The beads were washed three times, eluted with sample buffer and immunoblotted for either Rac1 or Cdc42. A similar assay, using the Rhoketin Rho binding domain as a GST fusion protein, was used to measure RhoA activation. For negative and positive controls, cell extracts were incubated with 1 mM GDP and 100 mM GTPgS, respectively.
Statistical analysis
Data were expressed as mean±s.d. Experiments were performed three times. Statistical significance was evaluated with Student's t test. Po0.05 was considered to be significant.
